JP2008539795A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008539795A5 JP2008539795A5 JP2008512587A JP2008512587A JP2008539795A5 JP 2008539795 A5 JP2008539795 A5 JP 2008539795A5 JP 2008512587 A JP2008512587 A JP 2008512587A JP 2008512587 A JP2008512587 A JP 2008512587A JP 2008539795 A5 JP2008539795 A5 JP 2008539795A5
- Authority
- JP
- Japan
- Prior art keywords
- ephrin
- azurin
- residues
- peptide
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 30
- 108010007337 Azurin Proteins 0.000 claims 15
- 239000008194 pharmaceutical composition Substances 0.000 claims 15
- 102000012803 ephrin Human genes 0.000 claims 14
- 108060002566 ephrin Proteins 0.000 claims 14
- 206010028980 Neoplasm Diseases 0.000 claims 10
- 201000011510 cancer Diseases 0.000 claims 9
- 102100023721 Ephrin-B2 Human genes 0.000 claims 8
- 108010044090 Ephrin-B2 Proteins 0.000 claims 8
- 108090000051 Plastocyanin Proteins 0.000 claims 8
- 238000004519 manufacturing process Methods 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 108091008815 Eph receptors Proteins 0.000 claims 4
- 102000050554 Eph Family Receptors Human genes 0.000 claims 3
- 101900113211 Pseudomonas aeruginosa Azurin Proteins 0.000 claims 3
- 101000595779 Ulva pertusa Plastocyanin Proteins 0.000 claims 3
- 108010092351 cupredoxin Proteins 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 230000001105 regulatory effect Effects 0.000 claims 3
- 102100040954 Ephrin-A1 Human genes 0.000 claims 2
- 108010043945 Ephrin-A1 Proteins 0.000 claims 2
- 102100033919 Ephrin-A2 Human genes 0.000 claims 2
- 108010043942 Ephrin-A2 Proteins 0.000 claims 2
- 102100033940 Ephrin-A3 Human genes 0.000 claims 2
- 108010043940 Ephrin-A3 Proteins 0.000 claims 2
- 102100033941 Ephrin-A5 Human genes 0.000 claims 2
- 102100033946 Ephrin-B1 Human genes 0.000 claims 2
- 108010044099 Ephrin-B1 Proteins 0.000 claims 2
- 102100023733 Ephrin-B3 Human genes 0.000 claims 2
- 108010044085 Ephrin-B3 Proteins 0.000 claims 2
- 101000925251 Homo sapiens Ephrin-A5 Proteins 0.000 claims 2
- 210000004204 blood vessel Anatomy 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 210000005036 nerve Anatomy 0.000 claims 2
- 230000011164 ossification Effects 0.000 claims 2
- 230000001575 pathological effect Effects 0.000 claims 2
- 230000001737 promoting effect Effects 0.000 claims 2
- 239000000523 sample Substances 0.000 claims 2
- 230000011664 signaling Effects 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000006332 Choriocarcinoma Diseases 0.000 claims 1
- 102100033942 Ephrin-A4 Human genes 0.000 claims 1
- 108010043938 Ephrin-A4 Proteins 0.000 claims 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 230000001537 neural effect Effects 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 210000004872 soft tissue Anatomy 0.000 claims 1
- 208000001608 teratocarcinoma Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68281205P | 2005-05-20 | 2005-05-20 | |
| US11/244,105 US7691383B2 (en) | 2004-10-07 | 2005-10-06 | Cupredoxin derived transport agents and methods of use thereof |
| US76474906P | 2006-02-03 | 2006-02-03 | |
| PCT/US2006/019684 WO2007018671A2 (en) | 2005-05-20 | 2006-05-19 | Compositions and methods for treating conditions related to ephrin signaling with cupredoxins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008539795A JP2008539795A (ja) | 2008-11-20 |
| JP2008539795A5 true JP2008539795A5 (enExample) | 2009-07-02 |
Family
ID=37727776
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008512587A Pending JP2008539795A (ja) | 2005-05-20 | 2006-05-19 | キュプレドキシンを用いたエフリン信号伝達に関する症状を治療するための組成物および方法 |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1888106A4 (enExample) |
| JP (1) | JP2008539795A (enExample) |
| KR (1) | KR20080040631A (enExample) |
| AU (1) | AU2006277009A1 (enExample) |
| BR (1) | BRPI0612424A2 (enExample) |
| CA (1) | CA2608512A1 (enExample) |
| IL (1) | IL187138A0 (enExample) |
| MX (1) | MX2007014598A (enExample) |
| NO (1) | NO20076391L (enExample) |
| WO (1) | WO2007018671A2 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9096663B2 (en) | 2001-02-15 | 2015-08-04 | The Board Of Trustees Of The University Of Illinois | Compositions and methods for treating conditions related to ephrin signaling with cupredoxins and mutants thereof |
| US7381701B2 (en) | 2001-02-15 | 2008-06-03 | The Borad Of Trustees Of The University Of Illinois | Compositions and methods for treating conditions related to ephrin signaling with cupredoxins |
| US7556810B2 (en) | 2005-07-19 | 2009-07-07 | The Board Of Trustees Of The University Of Ilinois | Compositions and methods to control angiogenesis with cupredoxins |
| UA97466C2 (ru) | 2004-10-07 | 2012-02-27 | Ананда Чакрабарти | Транспортирующие соединения - производные купредоксина и способы их применения |
| EP1904642A4 (en) | 2005-07-19 | 2008-11-26 | Univ Illinois | TRANSPORT AGENTS FOR CROSS-BREAKING BLOOD-BRAIN DISEASE AND INTRUSION IN BRAIN CANCER CELLS AND METHOD OF USE THEREOF |
| WO2007024368A2 (en) * | 2005-07-19 | 2007-03-01 | The Board Of Trustees Of The University Of Illinois | Compositions and methods to control angiogenesis with cupredoxins |
| EP2061498A4 (en) * | 2006-09-14 | 2009-11-04 | Univ Illinois | COMPOSITIONS AND METHOD FOR CANCER PREPARATION WITH CUPREDOXINES |
| WO2008086523A2 (en) * | 2007-01-11 | 2008-07-17 | The Board Of Trustees Of The University Of Illinois | Compositions and methods for treating conditions related to ephrin signaling with cupredoxins and mutants thereof |
| WO2009028639A1 (ja) | 2007-08-30 | 2009-03-05 | Daiichi Sankyo Company, Limited | 抗ｅｐｈａ２抗体 |
| KR101102829B1 (ko) * | 2008-09-12 | 2012-01-05 | 재단법인 제주테크노파크 | 구멍갈파래 추출물과 그것의 항염증제로서의 용도 |
| CN110090295B (zh) * | 2018-01-29 | 2022-12-23 | 武汉康理通科技有限公司 | Ephrin-B1在制备治疗炎症性肠病的药物中的用途 |
| WO2023205752A2 (en) * | 2022-04-22 | 2023-10-26 | University Of Miami | Ephrin ligand mimetic peptides for the treatment of neurodegenerative diseases |
| TW202547871A (zh) * | 2024-03-27 | 2025-12-16 | 美商麥第爾醫療公司 | 抗ｅｐｈｒｉｎ ｂ２抗體及使用方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002076380A2 (en) * | 2001-02-15 | 2002-10-03 | The Board Of Trustees Of The University Of Illinois | Cytotoxic factors for modulating cell death |
| US7491394B2 (en) * | 2001-02-15 | 2009-02-17 | The Board Of Trustees Of The University Of Illinois | Cytotoxic factors for modulating cell death |
-
2006
- 2006-05-19 AU AU2006277009A patent/AU2006277009A1/en not_active Abandoned
- 2006-05-19 WO PCT/US2006/019684 patent/WO2007018671A2/en not_active Ceased
- 2006-05-19 CA CA002608512A patent/CA2608512A1/en not_active Abandoned
- 2006-05-19 MX MX2007014598A patent/MX2007014598A/es active IP Right Grant
- 2006-05-19 JP JP2008512587A patent/JP2008539795A/ja active Pending
- 2006-05-19 BR BRPI0612424-0A patent/BRPI0612424A2/pt not_active IP Right Cessation
- 2006-05-19 EP EP06813192A patent/EP1888106A4/en not_active Withdrawn
- 2006-05-19 KR KR1020077028984A patent/KR20080040631A/ko not_active Ceased
-
2007
- 2007-11-04 IL IL187138A patent/IL187138A0/en unknown
- 2007-12-11 NO NO20076391A patent/NO20076391L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Farghaly et al. | An updated patent review of VEGFR-2 inhibitors (2017-present) | |
| Huang et al. | Design of substrate-based BCR-ABL kinase inhibitors using the cyclotide scaffold | |
| Ryan et al. | The Pan-RAF–MEK nondegrading molecular glue NST-628 is a potent and brain-penetrant inhibitor of the RAS–MAPK pathway with activity across diverse RAS-and RAF-driven cancers | |
| BR112021002250A2 (pt) | compostos de ligação ao receptor de il-2 | |
| CN107205996A (zh) | 胆管癌治疗剂 | |
| Mongre et al. | Emerging importance of tyrosine kinase inhibitors against cancer: quo vadis to cure? | |
| JPWO2015030021A1 (ja) | ピリミジン化合物を有効成分とする医薬組成物 | |
| ES2299242T3 (es) | Antagonistas de los receptores copulados a proteina g. | |
| Wang et al. | Highly efficient delivery of functional cargoes by a novel cell-penetrating peptide derived from SP140-like protein | |
| Qin et al. | Potent inhibition of HIF1α and p300 interaction by a constrained peptide derived from CITED2 | |
| WO2020093748A1 (zh) | 一种靶向线粒体的自组装蛋白质纳米颗粒的制备与应用 | |
| CN116322750A (zh) | 抗原特异性t细胞受体和嵌合抗原受体以及用于癌症免疫疗法的免疫信号传导调节中的使用方法 | |
| CN105198964A (zh) | 一种肿瘤靶向多肽、其制备方法及应用 | |
| Sahani et al. | Design, synthesis and characterization of HIV-1 CA-targeting small molecules: conformational restriction of PF74 | |
| Farooq et al. | Probing GPCR dimerization using peptides | |
| Lu et al. | Spatiotemporal regulation of store-operated calcium entry in cancer metastasis | |
| Mohr et al. | Rabbit cytochrome P450 4B1: A novel prodrug activating gene for pharmacogene therapy of hepatocellular carcinoma | |
| Qiao et al. | Bone morphogenetic protein receptor 1α promotes osteolytic lesion of oral squamous cell carcinoma by SHH‐dependent osteoclastogenesis | |
| Zaro et al. | Cytosolic delivery of a p16-peptide oligoarginine conjugate for inhibiting proliferation of MCF7 cells | |
| Sims-Mourtada et al. | Detection of Canonical Hedgehog Signaling in Breast Cancer by 131‐Iodine‐Labeled Derivatives of the Sonic Hedgehog Protein | |
| CN109862903B (zh) | 治疗性sall4肽 | |
| Schmitz et al. | A novel strategy for the generation of angiostatic kringle regions from a precursor derived from plasminogen | |
| Liu et al. | Hsp70 regulates CD24 expression and promotes metastasis and invasion of lung cancer via the MAPK/ERK signaling pathway | |
| JP5529609B2 (ja) | 標的結合部を有する薬剤運搬体 | |
| CN116178358A (zh) | 一种靶向c-Src激酶SH3结构域的化合物及其应用 |